Medifron DBT Co. Ltd (KQ:065650) — Market Cap & Net Worth
Market Cap & Net Worth: Medifron DBT Co. Ltd (065650)
Medifron DBT Co. Ltd (KQ:065650) has a market capitalization of $20.29 Million (₩29.94 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #25079 globally and #1793 in its home market, demonstrating a -0.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medifron DBT Co. Ltd's stock price ₩2250.00 by its total outstanding shares 13308217 (13.31 Million). Review Medifron DBT Co. Ltd total liabilities to assess the company's total debt and financial obligations.
Medifron DBT Co. Ltd Market Cap History: 2015 to 2026
Medifron DBT Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $30.45 Million to $20.29 Million (-4.72% CAGR).
Index Memberships
Medifron DBT Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.01% | #959 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.01% | #959 of 1384 |
Weight: Medifron DBT Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Medifron DBT Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medifron DBT Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Medifron DBT Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $30.45 Million | $8.22 Billion | -$1.71 Billion | 0.00x | N/A |
| 2016 | $38.86 Million | $13.10 Billion | -$3.96 Billion | 0.00x | N/A |
| 2017 | $49.06 Million | $20.91 Billion | -$11.45 Billion | 0.00x | N/A |
| 2018 | $42.88 Million | $19.89 Billion | -$5.56 Billion | 0.00x | N/A |
| 2019 | $42.39 Million | $17.41 Billion | -$1.78 Billion | 0.00x | N/A |
| 2020 | $35.94 Million | $31.41 Billion | -$3.52 Billion | 0.00x | N/A |
| 2021 | $23.27 Million | $49.25 Billion | -$6.76 Billion | 0.00x | N/A |
| 2022 | $10.37 Million | $45.29 Billion | -$12.02 Billion | 0.00x | N/A |
| 2023 | $8.87 Million | $42.88 Billion | -$1.96 Billion | 0.00x | N/A |
| 2024 | $10.96 Million | $58.46 Billion | -$80.36 Billion | 0.00x | N/A |
Competitor Companies of 065650 by Market Capitalization
Companies near Medifron DBT Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Medifron DBT Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Medifron DBT Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Medifron DBT Co. Ltd's market cap moved from $30.45 Million to $ 20.29 Million, with a yearly change of -4.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩20.29 Million | +12.22% |
| 2025 | ₩18.08 Million | +65.02% |
| 2024 | ₩10.96 Million | +23.60% |
| 2023 | ₩8.87 Million | -14.52% |
| 2022 | ₩10.37 Million | -55.43% |
| 2021 | ₩23.27 Million | -35.26% |
| 2020 | ₩35.94 Million | -15.21% |
| 2019 | ₩42.39 Million | -1.16% |
| 2018 | ₩42.88 Million | -12.59% |
| 2017 | ₩49.06 Million | +26.27% |
| 2016 | ₩38.86 Million | +27.59% |
| 2015 | ₩30.45 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Medifron DBT Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.29 Million USD |
| MoneyControl | $20.29 Million USD |
| MarketWatch | $20.29 Million USD |
| marketcap.company | $20.29 Million USD |
| Reuters | $20.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more